The H2 Peptide Report Roadmap: Five Hard Questions the September Edition Will Answer
From Baselines to Outcomes: What Changes in Four Months
The State of Peptides 2026 (H1 Edition) delivered the most comprehensive snapshot of the peptide industry ever published — 15,000 words mapping the market from GLP-1 economics to vendor transparency, from regulatory grey zones to Phase 3 trial timelines. But a snapshot is just that: a single frame.
The H2 edition, scheduled for September/October 2026, shifts from documenting the present to measuring movement. Where H1 asked "what is the state of the industry," H2 will answer "what actually happened." This is not a refresh — it's a score card.
Five Questions the H2 Edition Will Answer
The FDA Advisory Committee Result In July 2026, the FDA convened an advisory committee to review the legal status of six research peptides — BPC-157, TB-500, MOTS-c, and three others — under Section 503A of the Federal Food, Drug, and Cosmetic Act. The outcome of that hearing will determine whether these compounds remain available through compounding pharmacies or join the growing list of substances reclassified as bulk drug substances ineligible for compounding. The H2 edition will report the committee's decision, the FDA's formal follow-up action (which typically trails the advisory vote by 60–90 days), and the immediate market effects: which vendors pulled products, which pharmacies filed challenges, and where demand migrated.
Where Compounded-GLP-1 Demand Actually Went The compounded-semaglutide window closed in late 2025 when the FDA removed Ozempic and Wegovy from the shortage list. The H1 report documented the legal shift; H2 will quantify the market shift. Did patients switch to branded drugs, migrate to tirzepatide while it remained on the shortage list, move to telehealth platforms offering newer agents, or exit GLP-1 therapy entirely? The answer has implications for pricing, access models, and the durability of the peptide telehealth sector.
Retatrutide Phase 3 Interim Readouts Eli Lilly's triple-agonist obesity candidate — targeting GIP, GLP-1, and glucagon receptors — represents the next generation of metabolic peptides. Phase 3 trials launched in 2025; interim data readouts are expected throughout 2026. Where available, the H2 report will include efficacy benchmarks (weight loss at 24 weeks, comparison to tirzepatide cohorts), safety signals (discontinuation rates, gastrointestinal tolerability), and updated timelines for FDA submission. If retatrutide meets its endpoints, it resets the bar for what obesity pharmacotherapy can deliver. If it stumbles, the dual-agonist era extends.
The Vendor Transparency Index The H1 edition proposed a standardized scoring system for peptide suppliers — the Vendor Transparency Index — based on third-party testing, certificate-of-analysis publication, manufacturing disclosure, and customer service responsiveness. The H2 edition will publish live scores. Every supplier in The Peptide Alliance directory will receive a numerical transparency grade, updated quarterly and displayed alongside their listing. This shifts the site from a passive directory to an active quality filter, giving buyers a single metric to compare vendors who claim legitimacy.
Refreshed Directory Data and Segment Counts The peptide economy does not stand still. Clinics open and close, compounding pharmacies lose or gain 503A registration, telehealth platforms launch or pivot, and research suppliers rebrand or exit. The H2 edition will refresh the full vendor census: how many active peptide clinics operate in the U.S. and Canada, how many hold valid pharmacy licenses, which geographic markets saw the fastest growth, and which categories contracted. These are the hard counts that let the industry measure itself.
Why a Recurring Report Matters
A static industry analysis becomes obsolete the day it publishes. A recurring report — H1 in spring, H2 in fall — builds longitudinal value. It turns "the peptide market is worth $X billion" into "the market grew Y% in six months." It transforms "regulatory uncertainty looms" into "the FDA ruled, and here's what happened next." Baselines only matter if you measure movement.
The full H1 edition, including all chapters, data tables, and predictive frameworks, is live now at The State of Peptides 2026. Bookmark it. The H2 update will land in late September — same depth, new outcomes.
This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare provider before starting any peptide protocol.